Literature DB >> 21269929

Cholangiocarcinoma: principles and current trends.

George N Zografos1, Athanasios Farfaras, Flora Zagouri, Dimosthenis Chrysikos, Kostas Karaliotas.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) is a lethal cancer of the biliary epithelium, originating from the liver (intrahepatic), at the confluence of the right and left hepatic ducts (hilar) or in the extrahepatic bile ducts. It is a rare malignancy associated with poor prognosis. DATA SOURCES: We searched the PubMed/MEDLINE database for relevant articles published from 1989 to 2008. The search terms used were related to "cholangiocarcinoma" and its "treatment". Although no language restrictions were imposed initially, for the full-text review and final analysis, our resources only permitted the review of articles published in English. This review deals with the treatment of cholangiocarcinoma, the principles and the current trends.
RESULTS: The risks and prognostic factors, symptoms and differential diagnosis are thoroughly discussed. In addition, the tools of preoperative diagnosis such as endoscopic retrograde cholangiopancreatography, digital image analysis, fluorescence in situ hybridization and magnetic resonance cholangiopancreatography are reviewed. Moreover, the treatment of CCA is discussed.
CONCLUSIONS: The only curative treatment available is surgical management. Unfortunately, many patients present with unresectable tumors, the majority of whom die within a year of diagnosis. Surgical treatment involves major resections of the liver, pancreas and bile duct, with considerable mortality and morbidity. However, in selected cases and where indicated, appropriate management with aggressive surgery may achieve a good outcome with a prolonged survival expectancy.

Entities:  

Mesh:

Year:  2011        PMID: 21269929     DOI: 10.1016/s1499-3872(11)60001-5

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  20 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  Cholangiocarcinoma masquerading as an ovarian tumour.

Authors:  Darshan Khangura; Camelia Stefanovici; Mayur Brahmania; Dana Moffatt
Journal:  Can J Gastroenterol       Date:  2013-02       Impact factor: 3.522

3.  Circulating tumor cells in biliary cancer: First step or false step?

Authors:  G Thomas Budd
Journal:  J Gastrointest Oncol       Date:  2012-06

4.  Rapidly Progressing Primary Extrahepatic Bile Duct Signet-Ring Cell Carcinoma in a Caucasian Woman.

Authors:  Jessemae L Welsh; Omar Jaber; Marina Ivanovic; Frederick C Johlin; Rami G El Abiad; Gerald H Clamon; Mark C Smith; Carlos H F Chan
Journal:  J Gastrointest Cancer       Date:  2018-03

5.  Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI).

Authors:  Zeeshan Butt; Neehar D Parikh; Jennifer L Beaumont; Sarah K Rosenbloom; Karen L Syrjala; Amy P Abernethy; Al B Benson; David Cella
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

6.  Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy.

Authors:  Kosin Wirasorn; Thundon Ngamprasertchai; Jarin Chindaprasirt; Aumkhae Sookprasert; Narong Khantikaew; Ake Pakkhem; Piti Ungarereevittaya
Journal:  World J Gastrointest Oncol       Date:  2013-04-15

7.  Analysis of microscopic tumor spread patterns according to gross morphologies and suggestions for optimal resection margins in bile duct cancer.

Authors:  Ye Rim Chang; Kyoung Bun Lee; Jin-Young Jang; Chang-Sup Lim; Mee Joo Kang; Wooil Kwon; Woo Hyun Jung; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2014-04-19       Impact factor: 3.452

8.  Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin.

Authors:  In Woong Han; Jin-Young Jang; Kyoung Bun Lee; Mee Joo Kang; Wooil Kwon; Jae Woo Park; Ye Rim Chang; Sun-Whe Kim
Journal:  HPB (Oxford)       Date:  2013-12-06       Impact factor: 3.647

9.  Impact of medical and surgical intervention on survival in patients with cholangiocarcinoma.

Authors:  Amanda K Arrington; Rebecca A Nelson; Ann Falor; Carrie Luu; Rebecca L Wiatrek; Marwan Fakih; Gagandeep Singh; Joseph Kim
Journal:  World J Gastrointest Surg       Date:  2013-06-27

10.  Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch.

Authors:  Fangmei An; Sumitaka Yamanaka; Sarah Allen; Lewis R Roberts; Gregory J Gores; Timothy M Pawlik; Qing Xie; Masaharu Ishida; Esteban Mezey; Anne C Ferguson-Smith; Yuriko Mori; Florin M Selaru
Journal:  PLoS One       Date:  2012-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.